The Advanced Glycation End Product Nε-Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension

Background: Advanced glycation end products (AGEs) are implicated in the pathogenesis of vascular damage, especially in patients with diabetes and renal insufficiency. The oxidatively formed AGE N e -carboxymethyllysine (CML) is thought to be a marker of oxidative stress. Methods: Four hundred fifty patients with type 2 diabetes and nephropathy from the Irbesartan in Diabetic Nephropathy Trial cohort (mean age, 58 ± 8.2 years; 137 women, 313 men) with a mean glomerular filtration rate of 48.2 mL/min (0.80 mL/s; Modification of Diet in Renal Disease formula) were followed up for 2.6 years. Serum CML was measured by using an enzyme-linked immunosorbent assay. Relationships between CML levels, traditional risk factors, and cardiovascular and renal events were tested in Cox proportional hazards models. Results: Mean serum CML level was 599.9 ± 276.0 ng/mL, and mean hemoglobin A 1c level was 7.5% ± 1.6%. One hundred forty-three first cardiovascular events occurred during follow-up; 74 patients died, 44 of cardiovascular causes. Final multivariate analysis showed age (relative risk [RR], 1.87; confidence interval [CI], 1.13 to 3.11; P = 0.016 for the highest compared with lowest quartile), history of prior cardiovascular events (RR, 1.96; CI, 1.35 to 2.85; P P Conclusion: Serum CML level could not be identified as an independent risk factor for cardiovascular or renal outcomes in the examined population. This suggests that traditional risk factors might have a more important role for these end points or that other AGE compounds, as well as tissue AGE levels, might be of greater relevance compared with serum levels, which remains open to further study.

[1]  D. Daleke,et al.  The role of oxidative stress in diabetic complications , 2007, Cell Biochemistry and Biophysics.

[2]  J. Nagy,et al.  Serum carboxymethyllysine predicts mortality in hemodialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  Reindert Graaff,et al.  Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[4]  S. Genuth,et al.  Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. , 2005, Diabetes.

[5]  H. Stopper,et al.  Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients , 2005, Clinical chemistry and laboratory medicine.

[6]  Yusuke Suzuki,et al.  Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  M. Pfeffer,et al.  Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. , 2004, Kidney international. Supplement.

[8]  H. Parving,et al.  Progression of nephropathy in type 2 diabetic patients. , 2004, Kidney international.

[9]  R. de Caterina,et al.  Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. , 2004, Cardiovascular research.

[10]  G. Lang,et al.  Elevated serum levels of Nε-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema , 2004, Diabetologia.

[11]  U. Ott,et al.  Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. , 2004, Kidney international.

[12]  R. Gans,et al.  Simple non-invasive assessment of advanced glycation endproduct accumulation , 2004, Diabetologia.

[13]  J. Uribarri,et al.  Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  G. Müller,et al.  Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. , 2003, Diabetes care.

[15]  V. D’Agati,et al.  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.

[16]  M. Pfeffer,et al.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy , 2003, Annals of Internal Medicine.

[17]  T. Wendt,et al.  Are advanced glycation end products cardiovascular risk factors in patients with CRF? , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  M. Nangaku,et al.  Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. , 2002, Journal of the American Society of Nephrology : JASN.

[19]  C. Wanner,et al.  Advanced glycation end products and mortality in hemodialysis patients. , 2002, Kidney international.

[20]  J. Nagy,et al.  N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[22]  J. Baynes,et al.  Glycoxidation and lipoxidation in atherogenesis. , 2000, Free radical biology & medicine.

[23]  M. F. Weiss,et al.  Mechanisms for the formation of glycoxidation products in end-stage renal disease. , 2000, Kidney international.

[24]  E. Lewis,et al.  The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  M Ishii,et al.  [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.

[26]  S. Genuth,et al.  Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro , 1999, Diabetes.

[27]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[28]  C van Ypersele de Strihou,et al.  Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. , 1999, Kidney international.

[29]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[30]  T. Miyata,et al.  Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? , 1998, Kidney international.

[31]  R. Ziegler,et al.  AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.

[32]  E. Diamandis,et al.  The serum concentration of the advanced glycation end-product Nε-(carboxymethyl)lysine is increased in uremia: Technical Note , 1997 .

[33]  T. Lyons,et al.  Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. , 1997, The Journal of clinical investigation.

[34]  R. Bucala,et al.  Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Miyazaki,et al.  Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. , 1997, The Journal of clinical investigation.

[36]  E. Schleicher,et al.  Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. , 1997, The Journal of clinical investigation.

[37]  D. Hricik,et al.  Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. , 1996, Clinical transplantation.

[38]  C van Ypersele de Strihou,et al.  Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. , 1996, Journal of the American Society of Nephrology : JASN.

[39]  T. Lyons,et al.  The Advanced Glycation End Product, N-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (*) , 1996, The Journal of Biological Chemistry.

[40]  J. Baynes,et al.  New biomarkers of Maillard reaction damage to proteins. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  F. Harrell,et al.  Regression modelling strategies for improved prognostic prediction. , 1984, Statistics in medicine.